Dapagliflozin is an SGLT2 inhibitor used for type 2 diabetes, chronic kidney disease, and heart failure, providing glucose lowering via renal glucosuria and cardiorenal protection independent of glycemic status. It binds SGLT2 in proximal renal tubules, decreasing glucose and sodium reabsorption, which promotes natriuresis, hemodynamic benefits, and improved clinical outcomes. Trials and guidelines show reductions in kidney disease progression and heart failure events across eGFR ranges and regardless of diabetes, with benefits confirmed in DAPA‑HF and CKD populations. Contemporary pathways endorse its use in HF and CKD management frameworks.